Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04572750 · ClinicalTrials.gov registry record · NA
Promoting Benzodiazepine Cessation Through an Electronically-delivered Patient Self-management Intervention
A NA study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 170
- Enrollment target
NCT04572750: Completed NA study, sponsored by VA Office of Research and Development.
NCT04572750 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 170 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04572750, a NA study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
Study Summary
Benzodiazepines (e.g., Ativan, Xanax) are widely prescribed medications that are used mainly to treat anxiety and sleeping difficulties. Long-term use of benzodiazepine carries risks of physical dependence, addiction, falls and other accidents, and problems in thinking/concentrating. Researchers in Canada developed a printed self-help packet that enabled many individuals to reduce or cease taking benzodiazepines on their own. This study is designed to tailor that packet to the Veteran population, convert it to an app that people can use on their laptop or smart phone, and test whether the app helps promote benzodiazepine prescribing.
Interventions
- BEHAVIORAL EMPOWER-ED
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2024-07-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04572750
The ClinicalTrials.gov registry entry for NCT04572750 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EMPOWER-ED is the first listed.
NCT04572750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04572750 about?
NCT04572750 is a clinical study titled "Promoting Benzodiazepine Cessation Through an Electronically-delivered Patient Self-management Intervention". Benzodiazepines (e.g., Ativan, Xanax) are widely prescribed medications that are used mainly to treat anxiety and sleeping difficulties. Long-term use of benzodiazepine carries risks of physical dependence, addiction, falls and other accidents, and problems in thinking/concentrating. Researchers in ...
What is the current status of trial NCT04572750?
This trial is currently completed. It is a NA study. The enrollment target is 170 participants. The study started on 2022-06-01. Estimated completion is 2024-07-03.
What interventions are being tested in trial NCT04572750?
The interventions under investigation include: EMPOWER-ED (BEHAVIORAL).
Who is sponsoring clinical trial NCT04572750?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.